O
1.20
-0.06 (-4.76%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | OS Therapies Incorporated | - | - |
AIStockmoo 评分
0.6
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.63 |
|
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 33.38% |
| 机构持股比例 | 1.38% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Cm Management, Llc | 31 Dec 2025 | 400,000 |
| Mercer Global Advisors Inc /Adv | 30 Sep 2025 | 20,440 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合